H.R. 946 119th Congress
ORPHAN Cures Act
- Health
- Sponsor: Rep. Joyce, John [R-PA-13]
- Congress.gov ↗
Latest action, Feb 6, 2025: Sponsor introductory remarks on measure. (CR H535-536)
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
18 cosponsors
Sponsored by Rep. Joyce, John [R-PA-13] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
9 D · 9 R
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
ALKERMES, INC.
LMH STRATEGIC SOLUTIONS
7 reports
ALNYLAM PHARMACEUTICALS, INC.
LMH STRATEGIC SOLUTIONS
7 reports
7 reports
ASTRAZENECA PHARMACEUTICALS LP
W STRATEGIES, LLC
7 reports
7 reports
7 reports
7 reports
IONIS PHARMACEUTICALS, INC.
LMH STRATEGIC SOLUTIONS
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
All 25 of 79 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS | 7 | $4.0M | Q1 2025 | Q3 2026 | yes | |
| ALKERMES, INC. | LMH STRATEGIC SOLUTIONS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | LMH STRATEGIC SOLUTIONS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $28.6M | Q1 2025 | Q3 2026 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 7 | $9.9M | Q1 2025 | Q3 2026 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| DAIICHI SANKYO INC | 7 | $1.7M | Q1 2025 | Q3 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| INCYTE CORPORATION | 7 | $3.2M | Q1 2025 | Q3 2026 | yes | |
| IONIS PHARMACEUTICALS, INC. | LMH STRATEGIC SOLUTIONS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| JAZZ PHARMACEUTICALS, INC. | 7 | $3.2M | Q1 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 7 | $15.5M | Q1 2025 | Q3 2026 | yes | |
| LUNDBECK LLC | 7 | $1.1M | Q1 2025 | Q3 2026 | yes | |
| NEUROCRINE BIOSCIENCES, INC | 7 | $6.4M | Q1 2025 | Q3 2026 | yes | |
| NOVARTIS | 7 | $14.0M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $64.5M | Q1 2025 | Q3 2026 | yes | |
| PTC THERAPEUTICS, INC. | 7 | $1.3M | Q1 2025 | Q3 2026 | yes | |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| TRAVERE THERAPEUTICS | 7 | $1.2M | Q1 2025 | Q3 2026 | yes | |
| ALNYLAM PHARMACEUTICALS, INC. | TODD STRATEGY GROUP | 6 | $0 | Q1 2025 | Q2 2026 | yes |
| CALIFORNIA LIFE SCIENCES | W STRATEGIES, LLC | 6 | $0 | Q1 2025 | Q2 2026 | — |
| EMD SERONO INC | 6 | $4.5M | Q4 2025 | Q3 2026 | yes | |
| INCYTE CORPORATION | W STRATEGIES, LLC | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | TIBER CREEK GROUP | 5 | $0 | Q4 2025 | Q2 2026 | yes |
| ASTRAZENECA | TIBER CREEK GROUP | 5 | $440K | Q1 2025 | Q1 2026 | yes |